Abstract 728P
Background
Cervical function damage from fertility-sparing surgery reduces pregnancy success rate. Recently, immunotherapy has made significant advances in treating cervical cancer (CC). Herein, we conducted this study to evaluate the efficacy and safety of chemo + tislelizumab (TIS, a PD-L1 inhibitor) in young pts with CC who required fertility preservation.
Methods
In this trial, FIGO2018 stage IB1-IB3 or IIIC1r (localized cervical lesions) CC and having fertility needs were enrolled. Pts received 4 cycles chemo (175 mg/m2 paclitaxel + 70 mg/m2 cisplatin/AUC 5-6 carboplatin, Q3W) + TIS (200 mg, Q3W), followed by surgery-diagnostic cervical conization and sentinel lymph node (SLN) biopsy (IIIC1r stage with pelvic lymph node [PLN] systematic dissection)-upon achieving radiographic complete response (CR). After surgery, pts with pathological complete response (pCR) in all samples will undergo 2-cycle chemo + TIS, followed by TIS maintenance therapy (MT) for 1 year. If the first conization did not achieve pCR for localized cervical lesion only, a second conization was performed after 2-cycle chemo + TIS, followed by 1 year of TIS MT upon achieving pCR. Primary endpoint was pCR (SLN/PLNs + cervical conization) after surgery.
Results
Between Mar. 2022 and Apr. 2024, 8 pts (mean age 31 years) were enrolled, with 2 having stage IIIC1r disease. All 8 pts received chemo + TIS; of these, 6 pts completed 4 cycles, CR rate was 83.3%(5/6), and patients with CR received surgery. The pCR was 100% (5/5) in pts who underwent surgery, with 1 reaching a pCR after the second conization. Amenorrhea occurred in 3 of 5 pts, with 2 recovering normal menstruation post-chemo, and 1 had not returned after 3 weeks post-last chemo+TIS. During 4 cycles of chemo+TIS therapy (n=7), common TEAEs included rash (62.5%), neutropenia (62.5%), and leukopenia (62.5%), alanine aminotransferase increased (50.0%). At data cutoff (median follow-up, 9 months, range 2-25), 1 pt developed progression during MT, and 1 pt got pregnant 3 months post-MT.
Conclusions
Chemo + TIS could mediate tumor regression and eliminate micro-metastases with a tolerable safety profile, potentially preserving fertility in many pts previously considered ineligible.
Clinical trial identification
ChiCTR2300067495.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01